Therefore, to verify the hypothesis, in the present study high-fat feeding (HF) C57BL/6J mice were treated with a PPARγ agonist rosiglitazone (RSG) and the effects of PPARγ activation in vivo on HF mice and the expression of Gpc4 mRNA and protein in epididymal and inguinal depots, which were used as representative of visceral and subcutaneous fat respectively, were assessed. The gene discussed is PPARG; the disease is hydrops fetalis.